KARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.

Kardiologia Polska, the esteemed journal of the Polish Cardiac Society, has established itself as a vital resource in the field of cardiology and cardiovascular medicine since its inception in 1954. With an ISSN of 0022-9032 and an E-ISSN of 1897-4279, this journal serves as a platform for groundbreaking research and scholarly articles that contribute to the advancement of heart health. Although currently not an open access journal, it remains an essential reference for practitioners and researchers seeking to stay abreast of the latest developments in cardiovascular science. The journal reflects its scholarly depth through a Category Quartile of Q3 and a commendable Scopus ranking at the 48th percentile in its field. Published primarily in Poland, it caters to a global audience eager to explore comprehensive studies spanning clinical cardiology, innovative therapeutic approaches, and emerging cardiovascular trends. Join a thriving academic community by engaging with the invaluable insights and research contributions found within the pages of Kardiologia Polska.

HEART FAILURE REVIEWS is a premier academic journal published by Springer, dedicated to the dynamic field of cardiology and cardiovascular medicine. With an impressive Q1 ranking in 2023, the journal stands as a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments in heart failure management and research. Covering a broad spectrum of topics, including innovative therapies, epidemiology, and pathophysiology of heart failure, it fosters an environment for interdisciplinary collaboration. The journal is indexed with an ISSN of 1382-4147 and an E-ISSN of 1573-7322, ensuring widespread dissemination of knowledge. Although it does not currently offer open access options, its rigorous peer-review process guarantees high-quality content that contributes significantly to the scientific community. Established in 1996 and running through 2024, HEART FAILURE REVIEWS continues to be a leading platform for advancing understanding and treatment of heart conditions, making it an indispensable resource for all stakeholders in cardiac health.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

Expert Review of Anticancer Therapy, published by Taylor & Francis Ltd, is a distinguished journal focusing on the dynamic and ever-evolving field of oncology and pharmacology. Since its inception in 2001, this journal has played a pivotal role in disseminating critical reviews and analyses of novel anticancer therapies, fostering a deeper understanding among researchers and practitioners alike. With an impressive categorization in the 2023 Q2 quartiles for both Oncology and Pharmacology, it ranks #98 out of 272 in Pharmacology and #165 out of 404 in Oncology according to Scopus metrics, placing it well within the upper echelons of academic journals. The journal’s rigorous peer-review process ensures high-quality publications that are integral for advancing cancer research and therapeutic strategies. Although currently not an open access journal, it aims to bridge the gap between scientific discovery and clinical application, making it an essential resource for anyone involved in the fight against cancer.

PROGRESS IN PEDIATRIC CARDIOLOGY is a notable journal dedicated to advancing research and knowledge in the fields of pediatric cardiology and cardiovascular health in children. Published by Elsevier Ireland Ltd, this journal serves as a vital resource for clinicians, researchers, and healthcare professionals who engage with the complexities of heart diseases affecting pediatric populations. With ISSN 1058-9813 for print and 1558-1519 for online issues, it operates from Ireland and reflects a commitment to disseminating high-quality, peer-reviewed research since its inception in 1992. The journal is ranked in the Q3 category in both cardiology and pediatrics, indicating its relevance in the academic community, despite recent performance metrics showing room for growth within the competitive landscape. Researchers and practitioners can expect to find cutting-edge findings and clinical studies that aim to improve outcomes in pediatric cardiology. While it does not offer Open Access, the breadth of research covers various critical aspects, contributing significantly to the field's ongoing development.

Journal of Veterinary Cardiology is a leading scientific publication dedicated to the field of veterinary cardiology, published by ELSEVIER. With an ISSN of 1760-2734 and E-ISSN 1875-0834, this journal plays a crucial role in disseminating cutting-edge research and clinical insights into animal cardiovascular health. With a strong emphasis on the interrelations of veterinary science and physiology, it boasts an impressive ranking in the Q1 category for miscellaneous veterinary studies and a significant position at 69th percentile in general veterinary rankings according to Scopus. Researchers, professionals, and students are encouraged to engage with the journal's diverse array of articles that span basic research to clinical applications, bridging knowledge gaps in veterinary cardiology. This important resource showcases impactful studies from its inception in 1999 and remains a steadfast conduit for the advancement of knowledge in the field through 2024 and beyond.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.